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REVIEW

5q– myelodysplastic syndromes: chromosome 5q genes direct
a tumor-suppression network sensing actin dynamics
KM Eisenmann1,5, KJ Dykema2, SF Matheson1,3, NF Kent1, AD DeWard1, RA West1, R Tibes4,
KA Furge2 and AS Alberts1
1
Laboratories of Cell Structure & Signal Integration, Van Andel Research Institute, Grand Rapids, MI, USA; 2Computational
Biology, Van Andel Research Institute, Grand Rapids, MI, USA; 3Department of Biology, Calvin College, Grand Rapids, MI, USA
and 4Translational Genomics Clinical Research Service, Scottsdale, AZ, USA

Complete loss or interstitial deletions of chromosome 5
are the most common karyotypic abnormality in myelodysplastic syndromes (MDSs). Isolated del(5q)/5q– MDS
patients have a more favorable prognosis than those
with additional karyotypic defects, who tend to develop
myeloproliferative neoplasms (MPNs) and acute myeloid
leukemia. The frequency of unbalanced chromosome 5
deletions has led to the idea that 5q harbors one or more
tumor-suppressor genes that have fundamental roles in the
growth control of hematopoietic stem/progenitor cells
(HSCs/HPCs). Cytogenetic mapping of commonly deleted regions (CDRs) centered on 5q31 and 5q32 identiﬁed
candidate tumor-suppressor genes, including the ribosomal subunit RPS14, the transcription factor Egr1/Krox20
and the cytoskeletal remodeling protein, a-catenin.
Although each acts as a tumor suppressor, alone or in
combination, no molecular mechanism accounts for how
defects in individual 5q candidates may act as a lesion
driving MDS or contributing to malignant progression
in MPN. One candidate gene that resides between
the conventional del(5q)/5q– MDS-associated CDRs is
DIAPH1 (5q31.3). DIAPH1 encodes the mammalian
Diaphanous-related formin, mDia1. mDia1 has critical
roles in actin remodeling in cell division and in response to
adhesive and migratory stimuli. This review examines
evidence, with a focus on mouse gene-targeting experiments, that mDia1 acts as a node in a tumor-suppressor
network that involves multiple 5q gene products. The
network has the potential to sense dynamic changes
in actin assembly. At the root of the network is a
transcriptional response mechanism mediated by the
MADS-box transcription factor, serum response factor
(SRF), its actin-binding myocardin family coactivator,
MAL, and the SRF-target 5q gene, EGR1, which regulate
the expression of PTEN and p53-family tumor-suppressor
proteins. We hypothesize that the network provides a
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homeostatic mechanism balancing HPC/HSC growth
control and differentiation decisions in response to
microenvironment and other external stimuli.
Oncogene (2009) 28, 3429–3441; doi:10.1038/onc.2009.207;
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Introduction
Myelodysplastic syndromes (MDSs) are a heterogeneous collection of clonal hematopoietic disorders
that arise because of the defects in the control and
differentiation of hematopoietic stem cells and/or
hematopoietic progenitor cells (HSCs/HPCs) (Malcovati and Nimer, 2008). Myelodysplastic syndromes are
characterized by ineffective formation of hematopoetic
cell lineages with dysplastic features (Nimer, 2008a, b).
The clinical picture in MDS ranges from a spectrum of
anemias, leuko- or thrombocytopenias to severe transfusion-dependent peripheral pancytopenias. Thrombocytosis and leukocytosis occur in certain MDS subtypes
(Nimer, 2008b). Often the bone marrow is normo- to
hypercellular with paradoxically increased apoptosis
(Nimer, 2008a). Patients with MDS have an increased
risk of progression to acute myeloid leukemia (AML)
(Malcovati and Nimer, 2008). Median onset of MDS is
X65 years with a male predominance (Nimer, 2008b).
The most common karyotypic defects in MDS are
loss of all or part of chromosome 5 ((del)5 or 5q–),
chromosome 7, the Y chromosome and trisomy of
chromosomes 20 and 8 (Nolte and Hofmann, 2008).
Most patients have large interstitial deletions of 5q, and
when these deletions occur in the context of more
complex karyotypes, the prognosis is poor (Nimer,
2008b). The 5q deletions can be either more focused,
such as in MDS with isolated del(5q) (Nolte and
Hofmann, 2008), or quite large, including loss of the
entire long arm of chromosome 5 or monosomy of
chromosome 5 (5q–) (Olney and Le Beau, 2007).
Aberrations in chromosome 5 (either (del)5 or 5q–) are
frequently found in AML as well; however, often these
harbor different break points and deletion sizes (Nolte
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and Hofmann, 2008), and are associated with additional
cytogenetic changes and portent a worse prognosis
(Nimer, 2008b; Vardiman et al., 2009). A separate MDS
entity involving only chromosome 5q, and the focus of the
actin-sensing mechanism discussed below, is the former
5q– syndrome, now called MDS with isolated del(5q)
(herein referred to as ((del)5 or 5q–)) (Vardiman et al.,
2009). This syndrome is characterized by interstitial
deletions in chromosome 5q (different than those found
in AML) and commonly presents as anemia, mild
leukopenia and thrombocytosis with a female predominance, and has a more benign clinical course and good
response to lenalidomide (List et al., 2005).
Myeloproliferative neoplasms (MPNs) belong to the
group of clonal myeloid disorders with mainly proliferative changes in one or more hematopoetic lineages such as
thrombo-, leuko- or erythrocytes. Many oncogenic events
were shown to drive proliferation of these myeloid cells
(Tefferi and Gilliland, 2007). An overlapping group of
MDS–MPN exists, which shows both dysplastic and
proliferative features (Neuwirtova et al., 1996; Vardiman
et al., 2009). MPNs can transform into aggressive
phenotypes such as AML and this process is frequently
associated with additional 5q–/del(5q) chromosomal
aberrations found in certain MPN subtypes such as
primary myeloﬁbrosis (Santana-Davila et al., 2008).

Chromosome 5 abnormalities are among the most
common and frequent in MDS and in AML, respectively, as well as at progression of MPN to AML;
therefore, 5q has been postulated to harbor one or more
tumor-suppressor genes whose loss of function triggers
the progression to malignancy in a multi-step carcinogenesis program (Van den Berghe et al., 1985; Giagounidis et al., 2006).
Cytogenetic studies have attempted to classify
commonly deleted regions (CDRs) to pinpoint
candidate genes and/or to identify a common chromosome 5 break point (Le Beau et al., 1993; Boultwood
et al., 2007). Thus far, in (del)5 or 5q– MDS, no biallelic
deletions or point mutations have been identiﬁed
in genes associated with the 5q CDRs, leading to
the idea that genes residing at 5q are behaving as
haploinsufﬁcient tumor suppressors (Shannon and
Le Beau, 2008). The connection between changes
in expression of (del)5 or 5q– MDS tumor-suppressor
candidate genes and defects in growth control in vivo is
largely correlative and limited to associations in gene
expression in HPCs from (del)5 or 5q– patients. In this
review, we will discuss the molecular evidence and
mouse models supporting speciﬁc 5q candidates as
tumor suppressors of (del)5 or 5q– MDS and their roles
in growth control.

Figure 1 Commonly deleted regions (CDRs) and marker genes deﬁned by conventional cytogenetics. The two CDRs (Le Beau et al.,
1993; Boultwood et al., 2002) mapped by G-banding ﬂank the human gene DIAPH1 (DRF1) encoding human mammalian
Diaphanous-related formin (mDia1) and located at 5q31.3. The CDR boundaries are indicated by the open arrowheads; the RPS14
gene is located in CDR1 at 5q33.1, and both EGR1 (5.31.2) and CTNNA1 (5q31.2) genes are in CDR2.
Oncogene
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Assessing the 5q tumor-suppressor candidates
CDRs in 5q
Despite study-to-study and patient-to-patient variability, different groups have identiﬁed a number of putative
tumor-suppressor genes within the CDRs indicated in
Figure 1 (Boultwood et al., 2002; Liu et al., 2007). The
working list of genes deﬁned by the CDRs is relatively
limited and includes EGR1 (5q31.2), CTNNA1 (5q31.2)
and RPS14 (5q33.1). Conventional cytogenetic and
array-based comparative genomic hybridization analyses point to CDRs in aggressive MDS and AML
centered on 5q31, as well as a CDR associated with the
5q– subset of MDS localized to 5q32 (Van den Berghe
et al., 1985; Le Beau et al., 1993; Boultwood and Fidler,
1995; Horrigan et al., 2000; Boultwood et al., 2002;
Crescenzi et al., 2004; Giagounidis et al., 2004; Evers
et al., 2007; Herry et al., 2007).
The emergence of array-based, high-resolution, DNA
copy number analysis has allowed the chromosome 5q
region to be examined in more detail (Evers et al., 2007).
In addition, array-based approaches allow the determination of gene expression changes that accompany the
progression to acute leukemia. Interestingly, array-based
comparative genomic hybridization studies reinforce
previous cytogenetic mapping studies and highlight the
deletion of a fairly large region of chromosome 5 (5q31–
5q33; Figure 2a). Coupled with the lack of evidence for a
recurrent chromosome 5q break point, these studies
suggest that deregulation of one or more candidate genes
that map within the region of frequent 5q deletion
contributes to (del)5 or 5q– MDS development.
However, the identiﬁcation of speciﬁc candidate genes
that lie within the del(5q) region is complicated by the
global effects that chromosomal abnormalities have on
gene transcription. Gene expression proﬁling studies of
MDS and other tumors have shown that chromosome
losses lead to dramatic gene expression defects within
the deleted region (Greer et al., 2000). For example, on
the basis of transcriptional proﬁling, when cells isolated
from normal individuals were compared with cells from
(del)5 or 5q– MDS patients, 146 of the 644 genes
(23%) mapping to chromosome 5q were signiﬁcantly
downregulated in the (del)5 or 5q– MDS cells (Pellagatti
et al., 2006). In contrast, no genes within this
same region were signiﬁcantly downregulated in MDS
samples that contain a balanced chromosome 5q. Arraybased comparative genomic hybridization and other
microarray approaches have the potential to reveal
other genes that possess tumor-suppressor properties.
In each case, further functional studies are warranted to
determine which gene or network of genes are ‘drivers’
of MDS or simply ‘passengers’ of the chromosome 5q
deletion. Data emerging from multiple laboratories,
using diverse approaches including targeted knockdown
by interfering RNA (RNAi) and gene knockout mice,
are beginning to suggest that multiple 5q gene candidates harbor tumor-suppressor function.
The two CDRs mapped to 5q by conventional
cytogenetics ﬂank the DRF1/DIAPH1 (5q31.3) gene
(Figure 1), which encodes the mammalian Diaphanous-

related formin mDia1, a canonical member of the
formin family of ﬁlamentous (F-) actin assembly
proteins (discussed in more detail in following sections).
Furthermore, detailed microarray gene expression proﬁling of samples from MDS patients with detectable 5q
loss have shown that DIAPH1 expression is diminished
as signiﬁcantly as other notable candidate 5q– tumor
suppressors, including RPS14, EGR1 and CTNNA1
(Figure 2b). These data suggested a potential role for
loss of mDia1 function in the etiology of (del)5 or 5q–
MDS. This led us to target the murine Drf1 gene for
knockout (Peng et al., 2007); as previously published
and described in detail below, Drf1/ mice developed an
age-dependent myelodysplasia, similar in phenotype
to other knockout mice targeting genes residing in the
5q CDRs, including EGR1 and RPS14. First, let us
consider the 5q candidates historically associated with
the (del)5 or 5q– subset of MDS.
RPS14: a role for defective translation in MDS?
Ribosomal proteins have a critical function in protein
translation, and their dysregulation can promote tumorigenesis. RPS14 is an essential component of the 40S
ribosome. Consistent with tumor-suppressor function,
RPS14 gene (5q33.1) expression is diminished in (del)5
or 5q– MDS patients (Boultwood et al., 2007; Lehmann
et al., 2007; Ebert et al., 2008; Pellagatti et al., 2008;
Valencia et al., 2008), and RPS14 re-expression in
CD34 þ HSCs from affected patients slows proliferation
and rescues protein synthesis defects (Ebert et al., 2008).
It is noted that, Diamond-Blackfan anemia, which
shares several clinical features with MDS, is characterized by loss-of-function mutations or deletion of the
ribosomal components, RPS19, RPS24, RPS17 and
RPL35A (Gazda et al., 2006; Cmejla et al., 2007; Farrar
et al., 2008; Shannon and Le Beau, 2008).
Translational control is a critical target of common
oncogenes and tumor suppressors (reviewed in detail by
Bilanges and Stokoe (Bilanges and Stokoe, 2007)).
Interestingly, ribosomal proteins associated with Diamond-Blackfan anemia and (del)5 or 5q– MDS have
been proposed to function in p53 activation in response
to nucleolar stress. Indeed, RPS proteins have been
shown to inhibit p53 degradation by suppressing its
ubiquitination; conversely, haploinsufﬁciency of RPS
proteins could adversely affect ribosomal biogenesis
itself, consequently affecting the expression of tumor
suppressors such as p53 (Dai and Lu, 2008). Furthermore, RPS14 is thought to lie downstream of the
phosphoinositide 3-kinase (PI3K) signaling pathway,
which has a central role in governing translation. PI3K
is a bona ﬁde oncogene, as one of its catalytic subunits is
either ampliﬁed or mutated in various solid tumors
(Shayesteh et al., 1999; Samuels et al., 2004). The tumor
suppressor PTEN (phosphatase and tensin homolog) is
a phospholipid phosphatase that antagonizes PI3K by
dephosphorylating phosphatidylinositol triphosphate
(Tamguney and Stokoe, 2007).
PTEN is mutated in many late-stage tumors, including
those arising in the brain, prostate and endometrium
Oncogene
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Figure 2 Gene expression analysis of chromosome 5q in (del)5 or 5q– myelodysplastic syndromes (MDSs): comparison of DIAPH1/
DRF1 expression versus other candidate 5q tumor suppressors. (a) The percentage of patients having a copy number loss, computed
for 374 genomic locations on chromosome 5 (red lines indicate the centromere). MDS cells with chromosome 5q deletions were
examined by high-resolution array comparative genomic hybridization (n ¼ 10) as described in Evers et al. (2007). The region of most
frequent deletion maps between 5q23.3 and 5q33.3. To construct this plot, the Evers et al.’s DNA copy number data was obtained from
the Gene Expression Omnibus database (GEO, GSE8804; http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE8804),
replicate data was averaged, and genomic regions that had DNA copy number ratios o0.8 were considered regions of deletion. (b)
Relative gene expression as determined by microarray analysis for several candidate genes that map within the del(5q) region. Gene
expression values were obtained from CD34 þ cells isolated from normal individuals (n ¼ 11), from MDS patients who do not have a
detectable 5q loss (MDS, n ¼ 25) and from balanced and unbalanced del(5q) MDS patients (n ¼ 20). Signiﬁcant decreases in expression
are found in all of these genes in the 5q– versus normal individuals (Po0.05). To construct this plot, gene expression data generated by
Pellagatti et al. (2004, 2006, 2008) was obtained from GEO (GSE4619), replicate gene expression measurements were averaged and
data were plotted as log2-transformed intensity values.

(Li et al., 1997; Steck et al., 1997). The PI3K pathway seems to be activated in AML, but thus far, no
mutations of PTEN or other components such as AKT
have been found in AML (Tibes et al., 2008). Upregulation of PI3K activity contributes to malignant alterations
in proliferation, survival, metabolism, migration and
membrane trafﬁcking (Tamguney and Stokoe, 2007). In
addition to RPS14, other 5q genes are functionally
connected to PI3K, p53 and PTEN, including EGR1
and CTNNA1.
Early growth response-1 (Egr1) as a tumor suppressor
in (del)5 or 5q– MDS
Residing within the 5q CDR is the gene encoding Egr1,
a zinc-ﬁnger protein belonging to the WT1 family of
transcriptional regulators. EGR1 is an early response
gene and can mediate cellular responses to mitogens and
growth factors. Such activity is typically associated with
oncogenes, but interestingly, Egr1 possesses signiﬁcant
tumor-suppressor properties through its ability to
directly regulate key target genes, including TGFb1,
Oncogene

PTEN and p53 (TPR53) (Baron et al., 2006). Egr1 þ / or
Egr1/ mouse embryonic ﬁbroblasts bypass senescence
and, therefore, Egr1 was suggested to be an upstream
regulator or ‘gatekeeper’ of p53-dependent growth
regulation (Krones-Herzig et al., 2003). Egr1 is known
to regulate the promoters of both the PTEN and p53/
TP53 tumor-suppressor genes (Yu et al., 2007) and was
shown to physically interact with the p53 protein itself
(Liu et al., 2001). Egr1 upregulates PTEN expression in
response to both radiation and calyculin A (Virolle
et al., 2001, 2003). In addition, Egr1-mediated control of
p53 and PTEN was shown to have a role in DNA
damage-induced apoptosis in both prostate and breast
cancer cells (Adamson and Mercola, 2002; Adamson
et al., 2003; Yu et al., 2007). Collectively, these data
suggest a critical role for Egr1 in tumor suppression.
Beyond adhesion: a role for a-catenin in
hyperproliferation in myeloid progenitors
CTNNA1, the gene encoding a-catenin, resides at
5q31.2, within a CDR linked to (del)5 or 5q– MDS.
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Through an association with its well-known counterparts b-catenin and E-cadherin, the canonical roles
for a-catenin were to promote the assembly of
cell-cell junctions and to stabilize the actin cytoskeleton
by directly binding actin (reviewed extensively in
Benjamin and Nelson, (2008)). The quaternary complex
then stabilized cell-cell linkages to promote cell
adhesion.
However, recent data have prompted a modiﬁcation
of this classic model. In the updated model, a-catenin is
maintained at a low concentration proximal to the
plasma membrane and binds directly (albeit weakly) to
b-catenin, and subsequently complexes with E-cadherin.
Cell-cell adhesions drive E-cadherin clustering, and
a-catenin dissociates from b-catenin; the juxtamembrane a-catenin concentration is increased sufﬁciently
to promote its homodimerization. The a-catenin
homodimer undergoes a conformational change, preferentially binds to F-actin (as opposed to b-catenin/
E-cadherin) and promotes the bundling of actin
ﬁlaments (Rimm et al., 1995). Furthermore, the homodimer negatively regulates the Arp2/3 complex, impeding actin ﬁlament nucleation and elongation as well as
the formation of dynamic Arp2/3-dependent lamellae
(Gates and Peifer, 2005). Cell-cell adhesions would be
predicted to strengthen, potentially inhibiting cell
migration and invasion.
This model strongly suggests that changes in the
expression or subcellular localization of a-catenin may
inﬂuence disease progression. Diminished (or complete
loss of) a-catenin expression is observed in a host of
primary cancers (for example, breast, colorectal,
prostate), as well as in cancer cell lines derived from
primary tumors (for example, leukemia, leukocyte,
colon, prostate) (Benjamin and Nelson, 2008). Furthermore, human samples from MDS patients revealed a
loss of a-catenin protein expression within myeloid
progenitor cells (Desmond et al., 2007; Liu et al., 2007),
and, in some cancers, diminished a-catenin is a strong
predictor of invasive and metastatic behaviors, increased
survival and proliferation.
Recent studies suggest that a-catenin also functions in
disease progression through the regulation of cell
survival and apoptotic signaling pathways, independent
of its traditional association with E-cadherin. Conditional knockout of a-catenin in mouse epidermis showed
not only adhesion and migration defects in the skin, but
marked increases in Ras/MAPK signaling, hyperproliferation, and a signiﬁcant presence of multinucleated
cells (Vasioukhin et al., 2001). Conditional deletion of
a-catenin in the mouse central nervous system led to
severe hyperproliferation and dysplasia in the brain at
E13.5 that was attributed to decreased cellular apoptosis
and an accelerated cell cycle (Vasioukhin et al., 2001;
Lien et al., 2006). Re-introduction of a-catenin into HL60 myeloid leukemic cells (which harbor a 5q31 deletion
encompassing CTNNA1) suppressed cellular proliferation though enhancing apoptotic death (Liu et al., 2007).
Collectively, these data implicate a-catenin in the
control of cellular proliferation and cell death pathways
and imply that loss of a-catenin protein may also

adversely affect the ability of HSCs to migrate correctly
from the bone marrow.
The exact mechanism(s) of action that a-catenin
utilizes to speciﬁcally maintain proper hematopoiesis is
unclear. Is perturbation of a-catenin-dependent HSC
migration to and from the bone marrow sufﬁcient to
promote disease? This mechanism would presumably
involve disruption of the actin-binding/-bundling activities of a-catenin. This proposed role for actin bundling
proteins such as a-catenin in hematopoiesis is consistent
with a recent study from Qian et al. (Qian et al., 2008)
demonstrating a role for APC in hematopoietic stem
and progenitor cell survival . In that study, conditional
knockout of APC in the hematopoietic compartment led
to rapid and dramatic hematopoietic failure; speciﬁcally,
Apc-depleted mice experienced exhaustion of the
myeloid progenitor pool. Like a-catenin, Apc directly
binds to and bundles actin ﬁlaments (Moseley et al.,
2007), suggesting a role for actin bundling proteins in
the maintenance of the hematopoietic stem and progenitor compartments.
An expanding role for mDia1 in cytoskeletal regulation
The RPS14, EGR1 and CTNNA1 genes reside within
CDRs historically associated with (del)5 or 5q– MDS,
yet recent evidence suggests that DIAPH1/DRF1
inﬂuences the etiology of the disease. The DIAPH1
gene resides at 5q31.3, between the two most oft-cited
CDRs, and encodes the formin mDia1. Mining of the
pre-existing expression data shows that DIAPH1
expression is diminished to a similar degree as the other
5q– candidates (Figure 2b). We hypothesize that, in
conjunction with other proteins possessing tumorsuppressor activity, mDia1 and its ﬂanking neighbors
operate together as a functional node sensing cytoskeletal dynamics and whose deletion or dysfunction
promotes the development of (del)5 or 5q– MDS. First,
we provide a brief primer of the multiple functions of
mDia proteins.
Structure and function of mDia proteins
Structurally, all formin proteins share a formin homology-2 (FH2) domain (Higgs, 2005) (Figure 3a). The
FH2 domain nucleates and processively elongates actin
ﬁlaments by associating with growing barbed ends and
creating a biochemical environment favoring actin
monomer addition (Kovar, 2006) (Figure 3b). mDia
family formins are tightly regulated (Goode and Eck,
2007) by a Rho-controlled autoregulatory mechanism
mediated by the interaction between their N-terminal
(Dia-inhibitory, or DID) and C-terminal (Dia-autoregulatory, or DAD) domains (Alberts, 2001; Li and
Higgs, 2005). Activated GTP-bound Rho proteins bind
to the GTPase-binding domains and occlude DAD
binding to DID, thus alleviating its inhibitory inﬂuence
over the FH2 domain (Goode and Eck, 2007). Newly
generated actin ﬁlaments provide the underlying structures that drive changes in cell morphology to facilitate
events as divergent as cell division, intracellular trafﬁcking and chemotaxis (Chhabra and Higgs, 2007).
Oncogene
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Figure 3 Schematics of mammalian Diaphanous-related formin (mDia1) domain structure and mDia1-mediated actin ﬁlament
assembly. (a) Like all Diaphanous-related formins, mDia1 is autoregulated (Higgs, 2005). Dia-inhibitory domain (DID) weakly binds
to and inhibits the actin-nucleating formin homology-2 (FH2) domain (Li and Higgs, 2003). Dia-autoregulatory domain (DAD) acts as
a high-afﬁnity anchor or catch that is released on Rho binding to the GTPase-binding domain (Alberts, 2001; Wallar et al., 2006).
Bound GTP-Rho sterically interferes with DAD binding, thus releasing the inhibitory effects of DID over actin assembly. This leads to
activation of F-actin assembly and microtubule stabilization (Alberts, 2001; Palazzo et al., 2001; Wallar et al., 2006). (b) Spontaneous
actin assembly progresses from monomers to actin dimers and trimers; in the absence of assembly factors, these quickly dissociate.
FH2 domains, comprised of dimers linked by ﬂexible tethers, bind to and stabilize actin dimer intermediates. Formins processively
elongate ﬁlaments by creating an environment at the barbed ( þ ) end that favors monomer addition (Otomo et al., 2005). The crystal
structures (Xu et al., 2004; Otomo et al., 2005) of yeast and mammalian formins revealed unique ‘lasso and post’-like dimers between
FH2 domains. This so-called ‘tethered dimer’ allows for a dynamic association with the barbed end of growing ﬁlaments.

One mechanism of actin remodeling in response to
external stimuli includes Rho GTPase signaling
through their mDia formin effectors (Wallar and
Alberts, 2003). mDia formins remodel the actin cytoskeleton through binding of a variety of different Rho
GTPases (Figure 3), and the speciﬁcity of the actin-rich
structure is dictated by the association of distinct
mDia:Rho GTPase pairs. For instance, the interaction
between either mDia1 or mDia2 and activated RhoB is
integral to early endosomal trafﬁcking (Wallar et al.,
2007), although the interaction between mDia2 and
activated Cdc42 promotes ﬁlopodia formation (Peng
et al., 2003). mDia formins participate in changes in cell
morphology previously thought to depend largely on
activated Arp2/3. These processes include the dynamic
actin remodeling underlying ﬁlopodia/microspike
(Tominaga et al., 2002; Peng et al., 2003) and neurite
formation (Dent et al., 2007), phagocytosis (ColucciGuyon et al., 2005), vesicle trafﬁcking (Fernandez-Borja
et al., 2005; Wallar et al., 2007) and lamella/lamellipodial dynamics (Eisenmann et al., 2007; Gupton et al.,
2007; Yang et al., 2007).
Evidence for mDia1 in tumor suppression
Both mDia1 and the related mDia2 directly bind to
RhoB and act as effectors for RhoB signaling (Fernandez-Borja et al., 2005; Wallar et al., 2007). RhoB has a
critical role in apoptotic responses to DNA damage, and
Oncogene

the GTPase was shown to be a target of farnesyltransferase inhibitors (FTIs) (Lebowitz et al., 1997;
Prendergast, 2001a, b; Adini et al., 2003). RhoB, like
other Ras family members, is post-translationally
modiﬁed on a C-terminal motif (CAAX) by farnesylation. In cells treated with FTIs, RhoB shifts to become
geranyl-geranylated. This change in post-translational
modiﬁcation leads to enhanced activation of serumresponse factor (SRF)-mediated gene expression and
elevated sensitivity to DNA-damaging agents such as
doxorubicin (Lebowitz et al., 1997; Lebowitz and
Prendergast, 1998; Du et al., 1999). Although FTIs are
in active clinical development, no mechanism accounting for how they trigger programmed cell death has yet
been identiﬁed (Basso et al., 2006). Interestingly, a
recent study found that expression of a dominantnegative version of mDia1 not only enhanced tumorigenesis of Ras-transformed mouse embryonic ﬁbroblasts, but it also impeded the ability of FTIs to suppress
tumor growth (Kamasani et al., 2007). This result
indicates an important role for mDia1 in the FTI
response and suggests a functional relationship between
RhoB and mDia1 in tumor suppression. These observations also point to a potential mechanism for how FTIs
control tumor cell growth and supports exploration into
the clinical use of FTIs in the control of MPN and/or
MDS, an idea that has received some attention (Cortes
et al., 2002; Kurzrock, 2002; Kurzrock et al., 2002;
Huang et al., 2003; Kotsianidis et al., 2008).
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Potential mouse models of (del)5 or 5q– MDS
The effects of knocking out various murine equivalents
of 5q genes within the hematopoietic compartment have
been extensively documented; those genes targeted for
knockout include, EGR1, and other 5q genes lying
outside of the conventional 5q– CDRs, such as APC and
nucleophosmin-1 (NPM1). The resulting phenotypes are
compared within Table 1 and described brieﬂy below.
Egr1-targeted mice
Egr1 has central roles in the proliferation and localization of HSCs (Min et al., 2008). In the context of
myeloid function, Min et al. (Min et al., 2008) found
that EGR1/ mice have enhanced mobilization of HSCs
into the bloodstream. It was not clear whether the
phenotype was due to hyperproliferation that would
potentially cause the excess progenitors (stem cells) to
outstrip the capacity of the bone marrow to house them.
A second study, indicating Egr1 as a tumor suppressor,
determined that a subset of mice haploinsufﬁcient for
Egr1 develop myelodysplastic features. To test the
hypothesis that murine Egr1 had a role in tumor
suppression, Joslin et al. (Joslin et al., 2007) exposed
both Egr1 þ / and Egr1/ mice to N-ethyl-nitrosourea
(ENU). Although neither Egr1 þ / nor Egr1/ mice had
any outright myeloproliferative defects without ENU
treatment, both types of mice developed myeloproliferative defects at an increased rate with a shorter
latency period than wild-type mice treated with ENU.
The effects (summarized in Table 1) included an elevated
level of white blood cells, anemia and thrombocytopenia. Although this points to a tumor-suppressor role for

Table 1

The effects of knocking out murine equivalents of 5q genes

Mouse phenotype

Drf1

Egr1

Apc

Npm1

Elevated WBC
Lymphopenia
Monocytosis
Granulocytosis
Anemia
Thrombocytosis
Thrombocytopenia
Splenomegaly
Hepatomegaly
Extramedullary hematopoiesis
Loss of splenic organization
Myeloproliferative defects

þ
þ
þ
þ
þ
þ

þ

þ
þ
þ

þ

þ
þ
þ

þ
þ

þ
þ
þ


þ


þ

þ






þ

þ
þ
þ

þ
þ
þ
þ
þ
þ

Ineffective erythropoiesis in
Bone marrow
Spleen

þ
þ

þ
þ

þ
þ

þ
þ

Abbreviations: Egr1, early growth response-1; Npm1, nucleophosmin-1.
Unique features:
Drf1, myeloproliferative defects are age dependent.
Egr1, increased rate of myeloproliferation with shorter latency; an
absence of blasts.
Apc, depletion of hematopoietic stem cell and hematopoietic progenitor cell pools lead to immune failure.
Npm1, numerical and structural chromosomal abnormalities in
genomic DNA; 75% myeloid malignancy, 25% B- and T-cell
malignancy.

this transcription factor, Egr1 haploinsufﬁciency alone
does not seem to be sufﬁcient to trigger myeloproliferative disorders in mice.
Mx1-cre/Flox-Apc mice
The gene encoding the actin-bundling protein, APC
(5q22.2), lies outside the conventional CDR associated
with (del)5 or 5q– subsets of MDS (Moseley et al.,
2007). Ablating APC in developing myeloid progenitor
cells in mice results in a failure of normal hematopoiesis
due to an increase of apoptosis of HSC and HPC cells
(Qian et al., 2008). Exhaustion of HSC and HPC cells
leads to immune collapse and bone marrow failure.
These mice show decreased levels of white blood cells
and hemoglobin, are anemic and thrombocytopenic,
and display defective erythrocytic and myeloid differentiation. Ineffective erythropoiesis is a result of
differentiation arrest of late erythroblasts. Collectively,
the severe hematopoietic defects observed in Mx1-cre/
Flox-Apc mice suggest an important role for APC in the
maintenance of the hematopoietic stem and progenitor
compartments.
Npm1-targeted mice
Nucleophosmin is a nucleolar phosphoprotein having a
role in centrosomal duplication and genomic stability in
normal cells. Like APC, the gene encoding NPM1 lies
outside the conventional (del)5 or 5q– CDRs. Mice
heterozygous for NPM1 develop many features similar
to human MDS (Sportoletti et al., 2008); 75% of such
mice develop myeloid malignancies, whereas others
develop B- and T-cell malignancies. The peripheral
blood shows elevated levels of white blood cells and
leukemic blasts, myeloid expansion and proliferation,
and anemia and thrombocytopenia. Myeloid expansion
and increased levels of leukemic blasts are seen in the
bone marrow, spleen and liver. Splenomegaly is
observed, with atypical lymphoid cells replacing normal
spleen pulp.
Drf1-targeted/mDia1 knockout mice develop
age-dependent myelodysplasia
On the basis of the potential functional role between
RhoB and mDia1 in tumor suppression and its location
in the 5q region associated with MDS, we targeted the
murine Drf1 gene for knockout (Watanabe et al., 1997;
Peng et al., 2003). Our working hypothesis was that mice
would develop myeloproliferative defects or myelodysplasia. On birth, Drf1/ mice were developmentally and
morphologically indistinguishable from their wild-type
littermates, yet both Drf1 þ / and Drf1/ mice developed age-dependent myeloproliferative defects. The
resulting phenotype (detailed in Table 1) included
marked splenomegaly (attributed to hyperproliferation
within the spleen) and hypercellular bone marrow (due
to expansion of activated monocytes and macrophages).
Analysis of the erythroid compartment showed both a
signiﬁcant increase in the percentage of splenic cells in
the S phase and the expansion of erythroid precursors.
Collectively, the overall phenotype of the Drf1 knockout
Oncogene
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mouse, speciﬁcally the marked increased proliferation of
hematopoietic progenitors in vivo, supports a role for
mDia1 as a tumor suppressor for (del)5 or 5q– MDS.
The exact mechanism by which mDia1-mediated tumor
suppression is mediated remains unclear. An answer
may lie in the interrelated contribution(s) of neighboring genes within the 5q CDRs and the proteins
they encode, namely, Egr1, a-catenin and RPS14, as
described below.

Networking the 5q tumor-suppressor candidates: SRF as
a sensor for actin dynamics
On loss of each candidate 5q gene, including EGR1,
RPS14, CTNNA1 and DIAPH1/DRF1, similar defects
in hematopoiesis are observed; data from these studies
suggest that defects in expression of one or more
candidate genes mapping within the region of frequent
deletion contributes to MDS development. We hypothesize that there is a common functional mechanism
driving the progression toward MDS on loss of 5q. We
suggest that the link binding the 5q candidates is SRF,
which acts as an actin sensor to control the expression of
other 5q genes, including EGR1. And we propose that
the SRF sensor is controlled by two more 5q candidates:
mDia1 and a-catenin.
In addition to directly affecting the actin architecture
through the nucleation, elongation, and (in some cases)
bundling of actin ﬁlaments (Chhabra and Higgs, 2007),
mDia proteins regulate the expression of cytoskeletal
proteins by activating the transcriptional regulator SRF.
SRF was initially characterized as a regulator of
immediate-early gene expression caused by stimulation
of cells with growth factors (Treisman, 1986, 1996; Hill
and Treisman, 1995). Alone or in combination with
other transcription factors, SRF has a central role in
controlling transcriptional responses to growth factors
and other external stimuli (Posern and Treisman, 2006).
Over the past two decades, studies have shown that SRF
regulates the expression of numerous genes associated
with cytoskeletal remodeling, including the b-actin gene
(Sotiropoulos et al., 1999; Posern and Treisman, 2006).
Rho family members and their actin-nucleating effectors, including Rho-activated mDia1, are strong activators of SRF-mediated gene expression (Hill et al., 1995;
Sahai et al., 1998; Sotiropoulos et al., 1999; Tominaga
et al., 2000; Copeland and Treisman, 2002).

Furthermore, the 5q candidate a-catenin also modiﬁes
gene transcription through SRF. a-catenin was shown
to activate a serum-response element reporter (a readout
for SRF activity) (Merdek et al., 2008), potentially by
acting downstream of Rho/ROCK or through a
parallel, Rho-independent pathway. These ﬁndings were
consistent with a role for the downstream anti-proliferation effects of a-catenin, as SRF is known to induce
various genes associated with cell differentiation. The
loss of a-catenin expression and subsequent defective
growth control observed in many cancers may therefore
be mediated through dysfunction of this novel
a-catenin–SRF pathway.
Our proposed model is centered on the activity of
SRF, and incorporates an actin sensor controlling the
expression of other candidate 5q tumor-suppressor
genes, including EGR1 (Figure 4). How this actin sensor
might function? The SRF coactivator MAL bears
multiple RPEL motifs—so-called because of the amino-acid sequence on the protein that mediates actin
binding—that bind directly to monomeric actin; as
concentrations of G-actin decrease in the cytoplasm,
occupancy of the RPEL motifs diminishes (Posern et al.,
2004; Posern and Treisman, 2006; Guettler et al., 2008).
Non-actin-bound MAL, which normally shuttles between the nucleus and the cytoplasm, occupies the
nucleus and is free to activate SRF (Guettler et al.,
2008).
Within the nucleus, SRF binds to the conserved serum
response elements harbored in the promoters of
numerous genes, including that of EGR1. SRF can, in
fact, regulate the EGR1 promoter at no less than ﬁve
consensus serum-response element-/SRF-binding sites
(Figure 5a) (Mora-Garcia and Sakamoto, 2000). Hence,
through its dual activities of diminishing the cellular
pools of G-actin in the process of nucleating and
elongating F-actin ﬁlaments and of activating SRF,
mDia1 potentially acts as part of a node for regulating
the expression of Egr1. This mDia1-driven mechanism
may act in parallel with a-catenin-mediated SRF
activation. As Egr1 regulates the promoters of both
PTEN and p53/TP53 tumor-suppressor genes (Yu et al.,
2007) (Figure 5a), we postulate a role for the mDia1/
a-catenin-SRF-Egr1 node in promoting malignancy
through the disruption of PTEN and p53/TP53 expression (Figure 5b). To date, there are no data to suggest
that inactivating mutations of SRF or loss of SRF
expression coincides with malignancies. However,
expression of a constitutively active form of SRF fused

Figure 4 Mammalian Diaphanous-related formin (mDia)-directed serum response factor (SRF) activation by changes in F-actin
assembly. Growth factors or chemotactic stimuli propagate intracellular signals activating mDia1, in part, through binding to activated
Rho GTPases. This subsequently allows for nucleation and processive elongation of non-branched actin ﬁlaments from a G-actin
monomer pool. Diminishing concentration of actin monomer in the cytoplasm decreases the occupancy of RPEL motifs on the
transcriptional coactivator MAL. In the absence of RPEL occupancy by G-actin, MAL translocates to the nucleus to bind and
stimulate SRF (Posern et al., 2004; Posern and Treisman, 2006). In addition to other enhancer elements, the EGR1 promoter contains
ﬁve SRF-binding sites called serum-response elements (SREs). On docking to the SRE, MAL-bound SRF can promote the
transcription of numerous genes including those for EGR1 as well as b-actin. mDia1 has the unique capacity to both diminish the
cellular pools of G-actin in the process of nucleating and elongating F-actin ﬁlaments and activate SRF, thus amplifying the
downstream readout of gene transcription.
Oncogene

5q– myelodysplastic syndromes
KM Eisenmann et al

3437

Oncogene

5q– myelodysplastic syndromes
KM Eisenmann et al

3438

Figure 5 A model for an EGR1-dependent actin-sensing node in (del)5 or 5q– myelodysplastic syndromes that propagates p53/
PTEN. (a) Schematic of the EGR1 promoter, whose activity is regulated by at least ﬁve serum-response element (SRE) consensus sites.
In turn, Egr1 protein can act as a transcriptional activator to enhance the promoter activity of the tumor suppressor PTEN. (b) By
driving actin ﬁlament assembly and diminishing the cellular pools of G-actin, mammalian Diaphanous-related formin (mDia1) is a
potent activator of serum response factor (SRF), which, in turn, induces the expression of Egr1. Egr1 can act as a transcriptional
regulator, with target genes including TGF-b, p53 and PTEN, thereby regulating cell proliferation and survival signaling in response to
stress. Coupled with a-catenin-mediated SRF activation, multiple 5q candidates feed into this actin-sensing node, potentially
propagating p53/PTEN signaling through Egr1. Furthermore, through its association with the phosphoinositide 3-kinase (PI3K)
pathway, the 5q candidate, RPS14, can also amplify the p53/PTEN signal. Exquisite control of this actin-sensing mechanism centered
on 5q candidate tumor-suppressor genes would be critical to controlling the proliferation and proper migration of hematopoietic
progenitors and stem cells.

to a transcriptional activation domain from the viral
VP16 protein suppressed the ability of activated/
oncogenic Ras to transform cultured ﬁbroblasts (Kim
et al., 1994). Although this result was published roughly
15 years ago and was conﬁrmed by several groups, the
explanation for the result has never been adequate. Our
model, which assigns tumor-suppressor roles to SRF
and many of its 5q neighbors, deftly accounts for this
important observation.
Concluding remarks
No clear molecular mechanism accounts for how,
individually or together, 5q tumor-suppressor candidates either trigger MPNs or the myelodysplastic
phenotype, or support the progression to malignancy.
Candidate 5q tumor-suppressor genes mapped to
conventional CDRs in the 5q31–33 regions include
RPS14, EGR1 and CTNNA1, and disruption of their
expression leads to defects in hematopoiesis in mice.
Oncogene

By driving actin ﬁlament assembly and bundling,
respectively, mDia1 and a-catenin diminish cellular
pools of G-actin to activate SRF, which in turn induces
the expression of Egr1. Coupled with a-cateninmediated SRF activation, multiple 5q candidates feed
into this actin-sensing node, potentially affecting p53/
PTEN signaling through EGR1. Furthermore, through
its association with the PI3K pathway, the 5q candidate
RPS14 can also amplify the p53/PTEN signal. Hence,
multiple interdependent mechanisms exist within this
node that, on disruption of one or more candidates, may
lead to the progression towards malignancy in the (del)5
or 5q– subset of MDS.
An actin-dynamics sensing mechanism has the potential to control, or at least modulate, both the proliferation and proper migration of hematopoietic progenitors
and stem cells. The mechanism could facilitate the cells’
ability to make ‘go’ or ‘grow’ decisions as hematopoietic
cells differentiate and migrate to new compartments
while they progress through their differentiation
program.
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Intriguingly, APC (a 5q gene product) binds directly
and bundles F-actin and thus has the potential to
modulate SRF and Egr1-regulated gene expression.
Likewise, defective function and/or expression of Wiskott-Aldrich syndrome protein, a canonical regulator of
actin nucleation through the Arp2/3 complex and an
activator of SRF, could release the growth-control
machinery by affecting PTEN and p53 expression in the
myeloid malignancies that arise in affected WAS patients.
Thus, defects in an SRF-directed actin-dynamics sensing
tumor-suppression mechanism may have an additional
role in carcinogenesis in non-MDS tumors.
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